Idefirix has secured pricing and reimbursement in Sweden, the Netherlands and Germany, and on an ind...
Redeye expects to lower its fair value range thanks to soft sales, which were hurt by some delayed o...
Finnair reports Q1 results on Apr 27. The focus will be on the responses to the change which alters ...
Indexuppräkning i kombination med bra nettouthyrning medför stark tillväxt i hyresintäkterna inför 2...
Redeye adjusts BioArctic's valuation to reflect the terminated collaboration with AbbVie.
Redeye comments on Nanexa’s Q1 report and give our view of progress so far in 2022.
Detection Technology publishes its Q1 business review on April 27th.
Redeye is encouraged to see continued strong growth for the group in Q1, around 24% organic proforma...
Proptech-bolaget Compare-IT utvecklar och säljer styrsystemet Smart Homeline och smarta-hemtjänsten ...
Sdiptech's Q1 report is due on 29 April. We expect a solid quarter with 15% y/y sales growth and EBI...
Redeye is positive about the announcement of three new design wins, but states they were very much e...
Redeye leaves a comment on the announced rights issue and Q1 report published by Alzinova earlier th...
Redeye initiates coverage of Faron Pharmaceuticals, a Finnish biotech company focused on developing ...
Redeye endorses Coala Life receiving a new 510(k) approval for its Coala Heart Monitor to be used fo...
Bolagets tillgång till kritiska råvaror borgar för snabbare utveckling inom deras två gruvprojekt.
While we believe performance was solid in Q1, we expect revenue growth faces a tough comparison as Q...
Elanders will present its Q1 report on 21 April. We expect a somewhat muted quarter with a 13% y/y E...
Strategisk översyn Beijer Alma meddelade i samband med Q4-rapporten en översyn av ägandet i Habia Ca...
Redeye retains its positive view of Speqta, following a revised Investment Case due to Speqta’s dive...
Cline Scientific AB (”Cline” eller ”Bolaget”) tillkännagav den 12:e april att bolaget framgångsrikt ...
